Search Results - "Bogg, Orlaith"

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC) by Autio, Karen A, Higano, Celestia S, Nordquist, Luke, Appleman, Leonard J, Zhang, Tian, Zhu, Xin-Hua, Babiker, Hani, Vogelzang, Nicholas J, Prasad, Sandip M, Schweizer, Michael T, Madan, Ravi A, Billotte, Stephane, Cavazos, Nora, Bogg, Orlaith, Li, Ray, Chan, Kam, Cho, Helen, Kaneda, Megan, Wang, I-Ming, Zheng, Jenny, Tang, Szu-Yu, Hollingsworth, Robert, Kern, Kenneth A, Petrylak, Daniel P

“…BackgroundThis phase 1 study evaluated PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in two clinical states of prostate cancer (PC),…”
Get full text

First-in-human phase 1 dose escalation study of the KAT6 inhibitor PF-07248144 in patients with advanced solid tumors by Sommerhalder, David, Hamilton, Erika P., Mukohara, Toru, Yonemori, Kan, Mita, Monica M., Yamashita, Toshinari, Zheng, Jenny, Liu, LI, Maity, Arnab K., Homji Mishra, Natasha, Bogg, Orlaith, Li, Meng, LoRusso, Patricia

“…1054 Background: KAT6A and KAT6B regulate gene transcription via acetylation of histone H3K23 and their dysregulation drives lineage-specific gene expression…”
Get full text

A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer by Mukohara, Toru, Park, Yeon Hee, Sommerhalder, David, Yonemori, Kan, Kim, Sung-Bae, Kim, Jee Hyun, Iwata, Hiroji, Yamashita, Toshinari, Layman, Rachel M., Kim, Gun Min, Im, Seock-Ah, Lindeman, Geoffrey J, Rugo, Hope S., Liyanage, Marlon, Homji Mishra, Natasha, Maity, Arnab, Bogg, Orlaith, Liu, Li, Li, Meng, LoRusso, Patricia

“…3006 Background: Histone lysine acetyltransferase KAT6 regulates lineage specific gene transcription via H3K23 acetylation. PF-07248144 is a novel selective…”
Get full text